SBMU, Pharmaceutical Research Sciences
  • Register
  • Login
International Pharmacy Acta
  • Home
  • Journal Info
    • About
    • Aim and Scope
    • Ownership & Management
    • Indexing
    • Editorial Team
  • New Submission
  • Author Guidelines
    • Guideline
    • Types of articles
    • Templates
    • Publication Fees
  • Policies and Process
    • Publication Policy
    • Peer Review Process
    • Open Access Policy
    • plagiarism
    • Archiving
    • Privacy Statement
    • Copyright Notice
    • Waiver policy
    • Complaints Policy
    • Post- Publication Discussions and Corrections Policy
    • Advertisement and Marketing
  • Issues
    • Current
    • Archives
  • Contact us
Advanced Search
  1. Home
  2. Archives
  3. Vol. 1 No. 1 (2018): Pharmacy Updates 2018 (Congress Proceeding)
  4. Supplementary Issues: Reviews of books, journal, congress, other media Special issues, and Scientific news

Vol. 1 No. 1 (2018)

March 2018

New indolinone 1, 2, 3-triazole derivatives: Design, synthesis and anti-Alzheimer activity evaluation

  • Seyedeh Sara Mirfazli
  • Atefeh Maleki
  • Mina Saeedi

International Pharmacy Acta, Vol. 1 No. 1 (2018), 4 March 2018 , Page 119-119
https://doi.org/10.22037/ipa.v1i1.20063 Published: 2018-03-04

  • View Article
  • Download
  • Cite
  • Statastics
  • Share

Abstract

Novel 1,2,3-triazole indolinone derivatives have been synthesized. All the titled compounds were characterized by 1H NMR, 13C NMR, MS and IR spectral data. The in vitro AChE and BChE inhibitory activity of all the compounds were evaluated.

 Introduction:

Alzheimer disease is the most frequent cause of dementia, which is very common in elder population with high morbidity. Treatment of this disease is one of the most promising targets in medicinal chemistry researches. Design and synthesis of novel 1,2,3 diazole indolinone derivatives as cholinesterase inhibitor (ChEI), are investigated in this study. Indolinone derivatives with 1,2,3-triazole moiety have been recently reported as potential AChE and BuChE inhibitors. There is also, a growing interest in evaluating the biological activity of these compounds and their derivatives to investigate their role in the prevention of neurodegenerative diseases.

Methods and Results:

The target compounds were prepared via the 1-methyl-3-((prop-2-yn-1-yloxy)imino)indolin-2-one as an intermediate in click reaction with substituted benzyl halides in water and DMF as solvent in room temperature. All the synthesized compounds were characterized by 1H NMR, 13C NMR, MS and IR spectral data. The in vitro AChE and BuChE inhibitory activity of all the compounds were evaluated.

Conclusions:

In conclusion, various novel 1,2,3-triazole indolinone derivatives were designed, synthesized, and evaluated against AChE and BChE. All these results clearly confirmed the efficacy of the corresponding compounds for further drug discovery developments.

Keywords:
  • Synthesis, AChE, BuChE, Alzheimer Disease (AD), Indolinone, 1,2,3-triazole, Click reaction
  • PDF

How to Cite

Mirfazli, S. S., Maleki, A., & Saeedi, M. (2018). New indolinone 1, 2, 3-triazole derivatives: Design, synthesis and anti-Alzheimer activity evaluation. International Pharmacy Acta, 1(1), 119–119. https://doi.org/10.22037/ipa.v1i1.20063
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX
  • Abstract Viewed: 310 times
  • PDF Downloaded: 197 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

Information

  • For Readers
  • For Authors
  • For Librarians

Make a Submission

Make a Submission
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

Creative Commons License
This journal (and its contents) is licensed under a  Creative Commons Attribution-NonCommercial 4.0 International License.

 

                                                  Online ISSN: 2645-3266

                                                  Print ISSN: 2645-3258                                                 

Powered by OJSPlus